Patients under 21 with breast or colorectal cancer more likely to have aggressive disease
the ONA take:
According to two studies presented at the 2014 Clinical Congress of the American College of Surgeons in San Francisco, California, when breast and colorectal cancers occur in children, the diseases are aggressive.
Researchers at Seattle Children's Hospital in Seattle, Washington sought to investigate how breast cancer progresses when diagnosed in patients under age 21. Researchers identified 574 patients aged 21 or younger with breast cancer from the National Cancer Data Base of the American College of Surgeons and American Cancer Society. Results showed that younger patients were more likely to be African American, male, and uninsured.
Furthermore, these patients had worse outcomes that adult patients. Researchers also found a large delay between surgical treatment and radiation therapy. The delay is something the researchers hope to investigate further.
The other study was conducted by researchers at the Maine Medical Center in Portland, Maine who wanted to assess the outcomes of younger patients diagnosed with colorectal cancer. They identified 920 patients age 21 or younger. They found that younger patients were more likely diagnosed with advanced disease and found to have more aggressive tumors. Pediatric patients also had lower 5-year survival rates compared young adults.
When breast and colorectal cancers occur in children, the diseases are aggressive.
Breast and colorectal cancers rarely occur in children, but when they do, these conditions are more precarious, according to a pair of National Cancer Data Base (NCDB) studies presented this week at the 2014 Clinical Congress of the American College of Surgeons. Both breast cancer and colon cancer are known as adult conditions.
According to the American Cancer Society, 95 percent of new breast cancer cases occur in women age 40 and older. Colorectal cancer is also largely an adult cancer, with 90 percent of cases occurring in people who are age 50 and older.
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors
- Directly Informing Patients of Breast Cancer Risk, Options Improves Follow-Up Screening
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- CTCs Promising as Biomarker to Identify Lung Cancer Recurrence
- Hypofractionated RT, Conventional RT Comparable in Intermediate-Risk Prostate Cancer
- Social Functioning Scores for Young Cancer Survivors Remain Lower Than Their Peers
- Mortality Rates Highest Among Youngest Oncology Patients, Particularly Minorities
- Survey Reveals Research Priorities for Cancer Patients, Oncology Nurses
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|